US3745067A - Production of high purity iodine-131 radioisotope - Google Patents

Production of high purity iodine-131 radioisotope Download PDF

Info

Publication number
US3745067A
US3745067A US00001891A US3745067DA US3745067A US 3745067 A US3745067 A US 3745067A US 00001891 A US00001891 A US 00001891A US 3745067D A US3745067D A US 3745067DA US 3745067 A US3745067 A US 3745067A
Authority
US
United States
Prior art keywords
iodine
tellurium
radioactive
radioactive iodine
purity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00001891A
Inventor
H Arino
W Gemmill
H Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States, AS REPRESENTATIVE BY DEPARTMENT OF ENERGY
Original Assignee
Union Carbide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Union Carbide Corp filed Critical Union Carbide Corp
Application granted granted Critical
Publication of US3745067A publication Critical patent/US3745067A/en
Assigned to CINTICHEM, INC. reassignment CINTICHEM, INC. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: UNION CARBIDE CORPORATION, A CORP. OF NY
Anticipated expiration legal-status Critical
Assigned to UNITED STATES OF AMERICA, THE, AS REPRESENTATIVE BY THE DEPARTMENT OF ENERGY reassignment UNITED STATES OF AMERICA, THE, AS REPRESENTATIVE BY THE DEPARTMENT OF ENERGY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: CINTICHEM, INC.
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G21NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21GCONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/04Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators
    • G21G1/06Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by neutron irradiation
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B7/00Halogens; Halogen acids
    • C01B7/13Iodine; Hydrogen iodide
    • GPHYSICS
    • G21NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21GCONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/001Recovery of specific isotopes from irradiated targets
    • G21G2001/0063Iodine

Definitions

  • Radioactive iodine-131 is obtained in a stable chemical form by the dry distillation of a neutronirradiated tellurium containing material, such as tellurium dioxide, onto alumina followed by elution with a base such as a dilute alkaline solution.
  • Radioactive iodine-131 can be prepared by this process with a minimum of radioactive contamination to the immediate environment.
  • the radioactive iodine-131 obtained by this process is a versatile tracer and is useful to determine blood volume, cardiac output and the like.
  • iodine-131 Due to its relative short half-life (8.1 days) and high isotopic abundance, iodine-131 is particularly useful in medical research and diagnosis. It is well suited as a diagnostic tracer both in vivo and in vitro. For instance, it is well known that radioactive iodine isotopes are of great value in tests of thyroid function such as thyroid uptake, urinary iodine excretion, protein bound iodine conversion ratio and scanning of the thyroid or its metastases. In addition to medical uses, radioactive iodine isotopes can also be employed in industrial applications as a point radiation source. For example, they are useful for the determination of structural defects in metals and the like. However, when radioactive iodine isotopes are employed for medical research and diagnosis, the product must of necessity be extremely pure.
  • tellurium dioxide is irradiated with thermal neutrons and iodine-131 dry distilled and condensed in a cold trap.
  • this method has several disadvantages which do not render it ideally suited for consistently producing a product of a high degree of purity and in a chemically stable form.
  • it is often necessary to redistill the iodine a number of times. This necessarily requires the use of several coldtraps and numerous transfers of the product from one piece of apparatus to another within production facility such as a hot cell.
  • the distillation of gaseous iodine-131 can easily contaminate the working areas and, hence, the danger of radio-active contamination is great.
  • iodine-131 changes depending on the purity and acidity of the solution.
  • the iodine is present as iodide (I-) in an alkaline solution, and as molecular iodine (I or triiodide (1 in an acidic solution.
  • Molecular iodine is not desirable because it contaminates a laboratory by vaporization. Therefore, the iodide form is safe and more desirable.
  • the addition of any reducing chemical reagent is not desirable for many medical uses.
  • Another object of this invention is to provide a more efficient method for producing radioactive iodine- 131.
  • Another object of this invention is to provide a process for preparing radioactive iodine-131 in a high degree of purity and by an extremely reproducible and simple process.
  • An object of this invention is to produce radioactive iodine-131 by a method wherein the degree of recovery is high.
  • a further object of this invention is to provide a process for preparing radioactive iodine-131 of a high degree of purity and in a chemically stable form which is acceptable for medical research and diagnosis.
  • a still further object of this invention is to provide a method for the preparation of radioactive iodine-131 wherein the danger of radioactive contamination is minimized.
  • tellurium containing materia is meant tellurium metal, tellurium oxides, e.g., tellurium monoxide, tellurium dioxide, and tellurium salts, e.g., tellurium nitrate, tellurium sulfide, and the like.
  • Radioactive iodine-131 prepared by the process of this invention is obtained in a very high degree of purity and in a chemically stable form, i.e., as the iodide, and therefore suitable for use in medical research and diagnosis.
  • this process is extremely simple and rapid providing a high recovery of iodine.
  • the eluted iodine isotope is free of reducing agents.
  • the instant process provides a method which minimizes radioactive contamination of the working area.
  • the tellurium containing material for example tellurium dioxide
  • the tellurium material is irradiated with thermal neutrons. If the iodine-131 is to be used for medical diagnostic studies, it is important that the tellurium material be of a high degree of purity, that is, the total of all detectable elements be less than 0.1 weight percent. The selenium content must be less than 0.005 weight percent. If the tellurium material does not meet these limits, then it must be heated to remove the selenium. Heating is effected at temperatures of from about 550 C. to about 700 C. and higher for periods of up to one hour. It has been observed that optimum results are obtained when the tellurium material is heated at 700 C. for 30 minutes, broken up in a ball mill into a powder and refired at 700 C. for 30 minutes. It is broken up again in a ball mill until it has a fine texture.
  • the tellurium material is heated at 700 C. for 30 minutes, broken up in a ball mill into a powder and refire
  • the tellurium material for example, tellurium dioxide is then irradiated. After 200 hours of irradiation at a flux of approximately 3-5 10 n./om. /sec., greater than 14 curies of iodine-131 is obtained. A specific activity of greater than 2.5 X10 Ci/gm. will result one day after processing.
  • Irradiation of the target material to provide the desired isotope is well known and can be effected by placing the tellurium containing material in tht irradiation zone of a nuclear reactor, particle generator or neutron isotopic source. The irradiated tellurium containing material is then transferred to a quartz distillation vessel and mounted in a vacuum system.
  • the vessel is heated to a temperature of from about 450 to about 800 C. and the iodine-131 is distilled, and collected in a removable alumina column.
  • the iodine-131 is removed from the column by dissolution in a base, preferably a dilute alkaline solution.
  • bases include, among others, sodium carbonate, potassium hydroxide, ammonium hydroxide, calcium hydroxide, and the like.
  • the pH of the alkaline eluting solution employed is about 8 or higher, and preferably about 13.
  • Temperature is not necessarily critical and the elution step can be conducted conveniently at room temperature.
  • the present invention provides radioactive iodine-131 which is in a chemically stable form.
  • the oxidation state of iodine-131 to iodide is controlled without the addition of any reagents.
  • the alumina surface shifts the 1 equilibrium to iodide due to surface adsorption.
  • the chemical form of iodine-131 prepared by the process of this invention was investigated by ultraviolet spectroscopy (A. D. Awtrey and R. E. Connick, J.A.C.S. 73, 1842, 1951) and the paper chromatographic method (The United States Pharmacopia (X-VII), pp. 616-617, 1965).
  • the process of the present invention provides a simple method for the preparation of radioactive iodine-131 in a highly pure state and in a chemically stable form.
  • iodine-131 is obtained by this process having a radionuclide purity of g er th 99- cen hen the i di e so ution is intended for medical use, the solution can be sterilized according to known techniques without any adverse effect.
  • EXAMPLE I Commercially available tellurium dioxide having a selenium and total heavy metal content 'of les sthan 0.01 and 0.1 percent by weight respectively was fired in a precalibrated mufile furnace at 700 C., for 30 minutes. It was cooled again and ball milled until it had a fine facepowder texture.
  • Aluminum tubing, diameter and 0.035" wall thickness was cut into 20" lengths.
  • the tube was wire-brushed on the inside and a plug welded in one end.
  • the capsule was washed with trichloroethylene and acetone and dried in an oven. Approximately 300 gms. of TeO was weighed into the capsule.
  • the capsule was held in an aluminum block, a plug inserted and welded to the tubing. The integrity of the weld was determined by subjecting the capsule, immersed in water, to a partial vacuum of at least 27" of Hg.
  • the tellurium dioxide was then irradiated by reactor neutrons. After 200 hours of irradiation at a flux of approximately 3-5 x 10 n./cm. /sec., greater than 14 curies of iodine-131 were obtained.
  • the aluminum capsule was opened by cutting with a tubing cutter in front of a powder exhaust system to reduce the release of radioactive dust into the hot cell.
  • the tellurium dioxide was transferred to a quartz distillation flask and the empty capsule washed with 1 N NaOH and washings placed in a plastic bottle and capped.
  • the loaded flask was transferred to the hot cell and total activity checked by use of the in-cell gamma-ray monitor. Thereafter the flask was connected to the system containing a column of Woelm alumina and the system placed under vacuum. When the vacuum gauge indicated 30" of Hg, the furnace was raised up around the flask. Distillation was effected at 650 C. for about one hour. Thereafter, the system was allowed to cool and the column eluted with 5.0 milliliters of 0.1 N NaOH.
  • the iodine-131 concentration and radionuclidic purity was determined by gamma-ray spectroscopy. The concentration was about 3,000 mCi/ml. and the purity 99.9 percent. The pH of the final solution was 13.
  • the chemical form of iodine-131 was determined by ultra violet spectroscopy and paper chromatography to be iodide. No change was observed in the chemical form of the iodine for a period of three weeks.
  • a method for producing radioactive iodine-131 which comprises the steps of (a) irradiating a tellurium containing material with neutrons,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

HIGH PURITY RADIOACTIVE IODINE-131 IS OBTAINED IN A STABLE CHEMICAL FORM BY THE DRY DISTILLATION OF A NEUTRONIRRADIATED TELLURIUM CONTAINING METERIAL, SUCH AS TELLURIUM DIOXIDE, ONTO ALUMINA FOLLOWED BY ELUTION WITH A BASE SUCH AS DILUTE ALKALINE SOLUTION. RADIOACTIVE IODINE-131 CAN BE PREPARED BY THIS PROCESS WITH A MINIMUM OF RADIOACTIVE CONTAMINATION TO THE IMMEDIATE ENVIRONMENT. THE RADIOACTIVE IODINE-131 OBTAINED BY THIS PROCESS IS A VERSATILE TRACER AND IS USEFUL TO DETERMINE BLOOD VOLUME, CARDIAC OUTPUT AND THE LIKE.

Description

United States atent 3,745,67 PRODUCTIUN F HHGH PURITY IODINE-131 RADIOEOTOPE Hirofumi Arino, Sufiern, N.Y., Wayne J. Gemmill, Sr., Milford, Pa, and Henry H. Kramer, Mahwah, N.J., aNsszgnors to Union Carbide Corporation, New York, No Drawing. Filed Jan. 9, 1970, Ser. No. 1,891 Int. Cl. C0111 7/14; G21g 1/02 US. Cl. 176-16 8 Claims ABSTRACT OF THE DISCLOSURE High purity radioactive iodine-131 is obtained in a stable chemical form by the dry distillation of a neutronirradiated tellurium containing material, such as tellurium dioxide, onto alumina followed by elution with a base such as a dilute alkaline solution. Radioactive iodine-131 can be prepared by this process with a minimum of radioactive contamination to the immediate environment. The radioactive iodine-131 obtained by this process is a versatile tracer and is useful to determine blood volume, cardiac output and the like.
This invention relates to a novel process for the production of radioactive iodine. In one aspect, this invention relates to a novel process for the production of radioactive iodine-l31 in high yields. A further aspect of this invention is directed to a novel process for the produc tion of radioactive iodine-131 which can be obtained in a high degree of purity and in a stable chemical form.
Due to its relative short half-life (8.1 days) and high isotopic abundance, iodine-131 is particularly useful in medical research and diagnosis. It is well suited as a diagnostic tracer both in vivo and in vitro. For instance, it is well known that radioactive iodine isotopes are of great value in tests of thyroid function such as thyroid uptake, urinary iodine excretion, protein bound iodine conversion ratio and scanning of the thyroid or its metastases. In addition to medical uses, radioactive iodine isotopes can also be employed in industrial applications as a point radiation source. For example, they are useful for the determination of structural defects in metals and the like. However, when radioactive iodine isotopes are employed for medical research and diagnosis, the product must of necessity be extremely pure.
In the past, radioactive iodine isotopes have been prepared by a variety of methods. However, the processes employed to prepare isotopes do not always provide a product of the degree of purity necessary for medical applications, or are complex and time consuming. For example, M. Dous et al., US. Patent 3,114,608, discloses a process wherein reactor-irradiated Te0 target is dissolved into NaOH solution and iodine-131 distilled by adding hydrogen peroxide in the presence of sodium molybdate catalysis. C. R. Evans et al., British Patent 763,86S-1956, dry-distilled iodine-131 from TeO target into sodium sulfite solution. F. N. Case et al., US. Patent 3,282,655, dissolved the reactor irradiated U target into NaOH solution and distilled HI by acidifying the solution with H 80 The HI that was collected was further purified by Pt adsorption method. K. Taugbol and J. B. Dahl (Iener Report No. 52, Kjeller, Norway, 1957) separated iodine-131 from Te0 by one-step dry distillation.
In U.S. Patent 3,226,298 there is disclosed another process for making high purity radioactive iodine-131.
ice
In the referenced process tellurium dioxide is irradiated with thermal neutrons and iodine-131 dry distilled and condensed in a cold trap. However, this method has several disadvantages which do not render it ideally suited for consistently producing a product of a high degree of purity and in a chemically stable form. For example, in order to obtain a highly pure product, free of tellurium dioxide, it is often necessary to redistill the iodine a number of times. This necessarily requires the use of several coldtraps and numerous transfers of the product from one piece of apparatus to another within production facility such as a hot cell. Moreover, the distillation of gaseous iodine-131 can easily contaminate the working areas and, hence, the danger of radio-active contamination is great.
It has also been observed that the chemical form of iodine-131 changes depending on the purity and acidity of the solution. When the dry-distilled iodine is dissolved in an aqueous solution, the iodine is present as iodide (I-) in an alkaline solution, and as molecular iodine (I or triiodide (1 in an acidic solution. Molecular iodine is not desirable because it contaminates a laboratory by vaporization. Therefore, the iodide form is safe and more desirable. However, the addition of any reducing chemical reagent is not desirable for many medical uses. Hence, it is desired to control the chemical form of iodine-131 to iodide without adding a reducing agent and by providing a product which has a high degree of purity.
It is therefore an object of this invention to provide a more efficient method for producing radioactive iodine- 131. Another object of this invention is to provide a process for preparing radioactive iodine-131 in a high degree of purity and by an extremely reproducible and simple process. An object of this invention is to produce radioactive iodine-131 by a method wherein the degree of recovery is high. A further object of this invention is to provide a process for preparing radioactive iodine-131 of a high degree of purity and in a chemically stable form which is acceptable for medical research and diagnosis. A still further object of this invention is to provide a method for the preparation of radioactive iodine-131 wherein the danger of radioactive contamination is minimized. These and other objects will readily become apparout to those skilled in the art in the light of the teachings herein set forth.
It has now been discovered that the aforementioned objects can be achieved by a process which comprises the steps of:
(l) Irradiating a tellurium containing material with thermal neutrons;
(2) Dry distilling the radioactive iodine-131 from the said tellurium material onto alumina, and
(3) Selectively extracting the iodine-131 from the alumina with a base.
By the term tellurium containing materia as employed in the specification and claims, is meant tellurium metal, tellurium oxides, e.g., tellurium monoxide, tellurium dioxide, and tellurium salts, e.g., tellurium nitrate, tellurium sulfide, and the like.
Radioactive iodine-131 prepared by the process of this invention is obtained in a very high degree of purity and in a chemically stable form, i.e., as the iodide, and therefore suitable for use in medical research and diagnosis. In contrast to the known methods referred to above, this process is extremely simple and rapid providing a high recovery of iodine. Moreover, in contrast to the known methods, the eluted iodine isotope is free of reducing agents. Additionally, the instant process provides a method which minimizes radioactive contamination of the working area.
In the first step of the process of this invention, the tellurium containing material, for example tellurium dioxide, is irradiated with thermal neutrons. If the iodine-131 is to be used for medical diagnostic studies, it is important that the tellurium material be of a high degree of purity, that is, the total of all detectable elements be less than 0.1 weight percent. The selenium content must be less than 0.005 weight percent. If the tellurium material does not meet these limits, then it must be heated to remove the selenium. Heating is effected at temperatures of from about 550 C. to about 700 C. and higher for periods of up to one hour. It has been observed that optimum results are obtained when the tellurium material is heated at 700 C. for 30 minutes, broken up in a ball mill into a powder and refired at 700 C. for 30 minutes. It is broken up again in a ball mill until it has a fine texture.
The tellurium material, for example, tellurium dioxide is then irradiated. After 200 hours of irradiation at a flux of approximately 3-5 10 n./om. /sec., greater than 14 curies of iodine-131 is obtained. A specific activity of greater than 2.5 X10 Ci/gm. will result one day after processing. Irradiation of the target material to provide the desired isotope is well known and can be effected by placing the tellurium containing material in tht irradiation zone of a nuclear reactor, particle generator or neutron isotopic source. The irradiated tellurium containing material is then transferred to a quartz distillation vessel and mounted in a vacuum system. The vessel is heated to a temperature of from about 450 to about 800 C. and the iodine-131 is distilled, and collected in a removable alumina column. The iodine-131 is removed from the column by dissolution in a base, preferably a dilute alkaline solution.
Although a variety of bases have been found to be suitable for the elution step, sodium hydroxide is preferred. When it is employed, the resulting iodine isotope is obtained in the form of sodium iodide and hence suitable for use in medical diagnosis. However, other bases can also be employed if the radioactive iodine is intended for other than medical uses. Suitable bases include, among others, sodium carbonate, potassium hydroxide, ammonium hydroxide, calcium hydroxide, and the like. The pH of the alkaline eluting solution employed is about 8 or higher, and preferably about 13.
Temperature is not necessarily critical and the elution step can be conducted conveniently at room temperature.
As previously indicated, the present invention provides radioactive iodine-131 which is in a chemically stable form. The oxidation state of iodine-131 to iodide is controlled without the addition of any reagents. The alumina surface shifts the 1 equilibrium to iodide due to surface adsorption. The chemical form of iodine-131 prepared by the process of this invention was investigated by ultraviolet spectroscopy (A. D. Awtrey and R. E. Connick, J.A.C.S. 73, 1842, 1951) and the paper chromatographic method (The United States Pharmacopia (X-VII), pp. 616-617, 1965). The results showed that iodine-131 is present as iodide and does not change to any other forms for three weeks in a significant amount. Tellurium was not detected in the product solution by the cystein hydrochloride color test (the detection limit, 10- M). The radioactive contamination to the' environment was essentially eliminated and the operation was simplified.
As previously indicated, the process of the present invention provides a simple method for the preparation of radioactive iodine-131 in a highly pure state and in a chemically stable form. For instance, iodine-131 is obtained by this process having a radionuclide purity of g er th 99- cen hen the i di e so ution is intended for medical use, the solution can be sterilized according to known techniques without any adverse effect.
The following example is illustrative:
EXAMPLE I Commercially available tellurium dioxide having a selenium and total heavy metal content 'of les sthan 0.01 and 0.1 percent by weight respectively was fired in a precalibrated mufile furnace at 700 C., for 30 minutes. It was cooled again and ball milled until it had a fine facepowder texture.
Aluminum tubing, diameter and 0.035" wall thickness, was cut into 20" lengths. The tube was wire-brushed on the inside and a plug welded in one end. The capsule was washed with trichloroethylene and acetone and dried in an oven. Approximately 300 gms. of TeO was weighed into the capsule. The capsule was held in an aluminum block, a plug inserted and welded to the tubing. The integrity of the weld was determined by subjecting the capsule, immersed in water, to a partial vacuum of at least 27" of Hg.
The tellurium dioxide was then irradiated by reactor neutrons. After 200 hours of irradiation at a flux of approximately 3-5 x 10 n./cm. /sec., greater than 14 curies of iodine-131 were obtained.
After irradiation the aluminum capsule was opened by cutting with a tubing cutter in front of a powder exhaust system to reduce the release of radioactive dust into the hot cell. The tellurium dioxide was transferred to a quartz distillation flask and the empty capsule washed with 1 N NaOH and washings placed in a plastic bottle and capped.
The loaded flask was transferred to the hot cell and total activity checked by use of the in-cell gamma-ray monitor. Thereafter the flask was connected to the system containing a column of Woelm alumina and the system placed under vacuum. When the vacuum gauge indicated 30" of Hg, the furnace was raised up around the flask. Distillation was effected at 650 C. for about one hour. Thereafter, the system was allowed to cool and the column eluted with 5.0 milliliters of 0.1 N NaOH.
The iodine-131 concentration and radionuclidic purity was determined by gamma-ray spectroscopy. The concentration was about 3,000 mCi/ml. and the purity 99.9 percent. The pH of the final solution was 13. The chemical form of iodine-131 was determined by ultra violet spectroscopy and paper chromatography to be iodide. No change was observed in the chemical form of the iodine for a period of three weeks.
Although the invention has been illustrated by the preceding example, it is not to be construed as being limited to the materials employed therein, but rather, the invention encompasses the generic area as hereinbefore disclosed. Various modifications and embodiments of this invention can be made without departing from the spirit and scope thereof.
What is claimed is:
1. A method for producing radioactive iodine-131 which comprises the steps of (a) irradiating a tellurium containing material with neutrons,
(b) dry distilling the radioactive iodine-131 from said tellurium material onto alumina, and
(c) selectvely eluting the iodine-131 from said alumina with a base.
2. The method of claim 1 wherein said tellurium containing material is tellurium dioxide.
3. The method of claim 1 wherein said tellurium containing material is tellurium metal.
4. The method of claim 1 wherein said dry distilling is effected at a temperature of about 450 to about 800 C.
5. The process of claim 1 wherein said high purity radioactive iodine-131 is removed from said alumina with a dilute alkaline solution.
6. The process of claim 5 wherein said dilute alkaline so ution is, sodium hydroxid 7. The method of claim 1 wherein said eluted iodine- 131 has a radionuclidic purity of greater than 99.9 percent.
8. The method of claim 5 wherein said dilute alkaline solution containing radioactive iodine-131 is stiiriliz'ed.
References Cited UNITED STATES PATENTS Greene et a1. 23216 X Huising 23216 X Gemmill 176-46 X Case et a1. 17616 X CARL D. QUARFORTH, Primary Examiner E. E. LEHMANN, Assistant Examiner US. Cl. X.R.
US00001891A 1970-01-09 1970-01-09 Production of high purity iodine-131 radioisotope Expired - Lifetime US3745067A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US189170A 1970-01-09 1970-01-09

Publications (1)

Publication Number Publication Date
US3745067A true US3745067A (en) 1973-07-10

Family

ID=21698312

Family Applications (1)

Application Number Title Priority Date Filing Date
US00001891A Expired - Lifetime US3745067A (en) 1970-01-09 1970-01-09 Production of high purity iodine-131 radioisotope

Country Status (8)

Country Link
US (1) US3745067A (en)
JP (1) JPS5034716B1 (en)
CA (1) CA952854A (en)
DE (1) DE2100801C3 (en)
FR (1) FR2081422B1 (en)
GB (1) GB1329545A (en)
IL (1) IL35970A (en)
NL (1) NL7100250A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4729903A (en) * 1986-06-10 1988-03-08 Midi-Physics, Inc. Process for depositing I-125 onto a substrate used to manufacture I-125 sources
US4818468A (en) * 1977-08-03 1989-04-04 The Regents Of The University Of California Continuous flow radioactive production
US20110194662A1 (en) * 2010-02-11 2011-08-11 Uchicago Argonne, Llc Accelerator-based method of producing isotopes
CN104616713A (en) * 2015-01-26 2015-05-13 中国工程物理研究院核物理与化学研究所 Xenon target preparation device for reactor irradiation production of I-125 (iodine-125)
CN109416952A (en) * 2016-06-28 2019-03-01 国家放射性元素研究所 Prepare the iodine radioisotope especially method of the fraction of I-131, the iodine radioisotope especially fraction of I-131
CN109727693A (en) * 2019-01-08 2019-05-07 中国工程物理研究院核物理与化学研究所 A kind of connector for I-131 absorption bottle
CN110444312A (en) * 2019-09-03 2019-11-12 中国科学院近代物理研究所 Medical-isotope is separated from uranium fission product using cracking process131I

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB763865A (en) * 1954-09-27 1956-12-19 Atomic Energy Authority Uk Improvements in or relating to production of radioactive iodine 131
FR1335593A (en) * 1962-07-10 1963-08-23 Commissariat Energie Atomique Process for the production and extraction of iodine 131
US3226298A (en) * 1963-10-24 1965-12-28 Union Carbide Corp Process for making high purity radioactive iodine-131
AT243757B (en) * 1963-12-06 1965-11-25 Oesterr Studien Atomenergie Process for the production of <131> iodine in dissolved form

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818468A (en) * 1977-08-03 1989-04-04 The Regents Of The University Of California Continuous flow radioactive production
US4729903A (en) * 1986-06-10 1988-03-08 Midi-Physics, Inc. Process for depositing I-125 onto a substrate used to manufacture I-125 sources
US20110194662A1 (en) * 2010-02-11 2011-08-11 Uchicago Argonne, Llc Accelerator-based method of producing isotopes
US9177679B2 (en) * 2010-02-11 2015-11-03 Uchicago Argonne, Llc Accelerator-based method of producing isotopes
CN104616713A (en) * 2015-01-26 2015-05-13 中国工程物理研究院核物理与化学研究所 Xenon target preparation device for reactor irradiation production of I-125 (iodine-125)
CN104616713B (en) * 2015-01-26 2017-01-18 中国工程物理研究院核物理与化学研究所 Xenon target preparation device for reactor irradiation production of I-125 (iodine-125)
CN109416952A (en) * 2016-06-28 2019-03-01 国家放射性元素研究所 Prepare the iodine radioisotope especially method of the fraction of I-131, the iodine radioisotope especially fraction of I-131
CN109416952B (en) * 2016-06-28 2023-12-29 国家放射性元素研究所 Method for producing fractions of iodine radioisotopes, in particular I-131, fractions of iodine radioisotopes, in particular I-131
CN109727693A (en) * 2019-01-08 2019-05-07 中国工程物理研究院核物理与化学研究所 A kind of connector for I-131 absorption bottle
CN109727693B (en) * 2019-01-08 2022-09-23 中国工程物理研究院核物理与化学研究所 Connector for I-131 absorption bottle
CN110444312A (en) * 2019-09-03 2019-11-12 中国科学院近代物理研究所 Medical-isotope is separated from uranium fission product using cracking process131I

Also Published As

Publication number Publication date
DE2100801C3 (en) 1974-09-05
IL35970A (en) 1973-06-29
DE2100801A1 (en) 1971-07-15
DE2100801B2 (en) 1974-01-24
NL7100250A (en) 1971-07-13
CA952854A (en) 1974-08-13
GB1329545A (en) 1973-09-12
FR2081422B1 (en) 1974-08-30
JPS5034716B1 (en) 1975-11-11
IL35970A0 (en) 1971-03-24
FR2081422A1 (en) 1971-12-03

Similar Documents

Publication Publication Date Title
EP0541543B1 (en) Soluble irradiation targets and methods for the production of radiorhenium
Nadkarni et al. Determination of the noble metals in geological materials by neutron activation analysis
Morgan et al. The determination of uranium and thorium in rocks by neutron activation analysis
Purkayastha et al. The yields of 129I in natural and in neutron-induced fission of uranium
Smales The determination of small quantities of uranium in rocks and minerals by radioactivation
US3745067A (en) Production of high purity iodine-131 radioisotope
Finston et al. The radiochemistry of cesium
Gijbels Determination of noble metals by neutron-activation analysis
Ohno Determination of iodine and bromine in biological materials by neutron-activation analysis
Jenkins Determination of small quantities of thorium by radioactivation
Parry Simultaneous determination of the noble metals in geological material by radiochemical neutron-activation analysis
Caletka et al. Trace characterization of tantalum by NAA involving pre-and post-irradiation separations
Arino et al. Production of high purity iodine-131 radioisotope
Terakado et al. Precise determination of rare earth elements in rocks by neutron activation analysis: A pre-irradiation group separation method and a problem concerning granitic rock analysis
Bokhari et al. Separation of no-carrier-added arsenic-77 from neutron irradiated germanium
Wu et al. Application of neutron activation analysis in a fission molybdenum separation study
Gladney et al. Simultaneous determination of tellurium and uranium by neutron activation analysis
Morris et al. The determination of gallium in rocks by neutron-activation analysis
Goetz et al. Biochemical studies of current environmental levels of trace elements: cyclotron production of radiothallium and its use for metabolic investigations on laboratory animals
Mincher et al. The separation of 99 Tc from mixed fission products and its determination by neutron activation
Rebagay et al. Simultaneous determination of zirconium and hafnium in standard rocks by neutron activation analysis
McNamara et al. Potential defect structure effects in the volatility separation of sub-picogram quantities of fission and activation products from an irradiated UO 2 matrix
Lyle et al. A separation of protactinium from neutron-irradiated thorium
Roberts et al. The radiochemistry of uranium, neptunium and plutonium: an updating
US3339072A (en) Method of tracing iodine using i-129

Legal Events

Date Code Title Description
AS Assignment

Owner name: CINTICHEM, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION CARBIDE CORPORATION, A CORP. OF NY;REEL/FRAME:003951/0224

Effective date: 19810428

Owner name: CINTICHEM, INC., A CORP. OF DE, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UNION CARBIDE CORPORATION, A CORP. OF NY;REEL/FRAME:003951/0224

Effective date: 19810428

Owner name: CINTICHEM, INC., LONG MEADOW ROAD, P.O. BOX 204, T

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:UNION CARBIDE CORPORATION, A CORP. OF NY;REEL/FRAME:003951/0224

Effective date: 19810428

AS Assignment

Owner name: UNITED STATES OF AMERICA, THE, AS REPRESENTATIVE B

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:CINTICHEM, INC.;REEL/FRAME:005939/0818

Effective date: 19911127